Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Quantifying renal allograft loss following early antibody-mediated rejection.

Orandi BJ, Chow EH, Hsu A, Gupta N, Van Arendonk KJ, Garonzik-Wang JM, Montgomery JR, Wickliffe C, Lonze BE, Bagnasco SM, Alachkar N, Kraus ES, Jackson AM, Montgomery RA, Segev DL.

Am J Transplant. 2015 Feb;15(2):489-98. doi: 10.1111/ajt.12982. Epub 2015 Jan 21.

PMID:
25611786
2.

Surgical management of early and late ureteral complications after renal transplantation: techniques and outcomes.

Berli JU, Montgomery JR, Segev DL, Ratner LE, Maley WR, Cooper M, Melancon JK, Burdick J, Desai NM, Dagher NN, Lonze BE, Nazarian SM, Montgomery RA.

Clin Transplant. 2015 Jan;29(1):26-33. doi: 10.1111/ctr.12478. Epub 2014 Dec 12.

PMID:
25312804
3.

Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA.

Transplantation. 2014 Oct 27;98(8):857-63. doi: 10.1097/TP.0000000000000298.

PMID:
25121475
4.

Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients.

Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, Nazarian SM, Lonze BE, Montgomery RA, Kraus ES.

Transplantation. 2014 Feb 27;97(4):440-5. doi: 10.1097/01.TP.0000437177.40551.f4.

PMID:
24531821
5.

Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants.

Sharif A, Kraus ES, Zachary AA, Lonze BE, Nazarian SM, Segev DL, Alachkar N, Arend LJ, Bagnasco SM, Racusen LC, Montgomery RA.

Transplantation. 2014 Mar 15;97(5):541-7. doi: 10.1097/01.TP.0000442513.27641.7e.

PMID:
24521779
6.

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.

Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, Singer AL, Carter-Monroe N, Nazarian SM, Segev DL, Streiff MB, Montgomery RA.

Am J Transplant. 2014 Feb;14(2):459-65. doi: 10.1111/ajt.12540. Epub 2014 Jan 8.

7.

Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-Incompatible Transplant Recipients.

Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, Nazarian SM, Lonze BE, Montgomery RA, Kraus ES.

Transplantation. 2013 Oct 29. [Epub ahead of print]

PMID:
24173106
8.

Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients.

Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM, Desai NM, Dagher NN, Segev DL, Montgomery RA, Singer AL.

Transplantation. 2012 Jul 27;94(2):165-71. doi: 10.1097/TP.0b013e318253f7b6.

PMID:
22735712
9.

Operative start times and complications after kidney transplantation.

Shaw TM, Lonze BE, Feyssa EL, Segev DL, May N, Parsikia A, Campos S, Khanmoradi K, Zaki RF, Ortiz JA.

Clin Transplant. 2012 May-Jun;26(3):E177-83. doi: 10.1111/j.1399-0012.2012.1622.x. Epub 2012 May 7.

PMID:
22563648
10.

In vitro and ex vivo delivery of short hairpin RNAs for control of hepatitis C viral transcript expression.

Lonze BE, Holzer HT, Knabel MK, Locke JE, DiCamillo GA, Karhadkar SS, Montgomery RA, Sun Z, Warren DS, Cameron AM.

Arch Surg. 2012 Apr;147(4):384-7. doi: 10.1001/archsurg.2011.1250.

PMID:
22508787
11.

Outcomes of renal transplants from Centers for Disease Control and Prevention high-risk donors with prospective recipient viral testing: a single-center experience.

Lonze BE, Dagher NN, Liu M, Kucirka LM, Simpkins CE, Locke JE, Desai NM, Cameron AM, Montgomery RA, Segev DL, Singer AL.

Arch Surg. 2011 Nov;146(11):1261-6. doi: 10.1001/archsurg.2011.267.

PMID:
22106317
12.

Desensitization in HLA-incompatible kidney recipients and survival.

Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL.

N Engl J Med. 2011 Jul 28;365(4):318-26. doi: 10.1056/NEJMoa1012376.

13.

Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.

Montgomery RA, Lonze BE, Jackson AM.

Curr Opin Organ Transplant. 2011 Aug;16(4):439-43. doi: 10.1097/MOT.0b013e32834897c1. Review.

PMID:
21666478
14.

Outcomes and discard of kidneys from pediatric donors after cardiac death.

Dagher NN, Lonze BE, Singer AL, Simpkins CE, Desai NM, Montgomery RA, Segev DL.

Transplantation. 2011 Apr 15;91(7):765-71. doi: 10.1097/TP.0b013e31820cfd27.

PMID:
21285917
15.

Stem cell mobilization is life saving in an animal model of acute liver failure.

Mark AL, Sun Z, Warren DS, Lonze BE, Knabel MK, Melville Williams GM, Locke JE, Montgomery RA, Cameron AM.

Ann Surg. 2010 Oct;252(4):591-6. doi: 10.1097/SLA.0b013e3181f4e479.

PMID:
20881764
16.

Operative start times and complications after liver transplantation.

Lonze BE, Parsikia A, Feyssa EL, Khanmoradi K, Araya VR, Zaki RF, Segev DL, Ortiz JA.

Am J Transplant. 2010 Aug;10(8):1842-9. doi: 10.1111/j.1600-6143.2010.03177.x.

17.

Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.

Lonze BE, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, Zachary AA, Montgomery RA.

Am J Transplant. 2010 Sep;10(9):2154-60. doi: 10.1111/j.1600-6143.2010.03191.x. Epub 2010 Jul 15.

18.

Eculizumab and renal transplantation in a patient with CAPS.

Lonze BE, Singer AL, Montgomery RA.

N Engl J Med. 2010 May 6;362(18):1744-5. doi: 10.1056/NEJMc0910965. No abstract available.

19.

Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.

Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, Anders RA, Rother RP, Brodsky RA, Cameron AM.

Liver Transpl. 2009 May;15(5):540-3. doi: 10.1002/lt.21714.

PMID:
19399743
20.

Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants.

Stewart ZA, Lonze BE, Warren DS, Dagher NN, Singer AL, Montgomery RA, Segev DL.

Am J Transplant. 2009 May;9(5):1048-54. doi: 10.1111/j.1600-6143.2008.02545.x. Epub 2009 Mar 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk